ProsTIC Registry of Men Treated With PSMA Theranostics

This is a registry study for men with prostate cancer that no longer responds to hormone therapy (called castration-resistant prostate cancer) who are being treated with a radioactive targeted therapy called Lutetium-PSMA (Lu-PSMA). The study collects real-world data on how patients do on this treatment. **You may be eligible if...** - You have been diagnosed with metastatic castration-resistant prostate cancer (mCRPC) - You have tried and either progressed on or couldn't tolerate a newer hormone-blocking drug (such as abiraterone or enzalutamide) - You have received at least one taxane chemotherapy drug, OR your doctor considers you too unwell for chemotherapy - You have been referred to nuclear medicine and are being considered for Lu-PSMA therapy **You may NOT be eligible if...** - You have not progressed on any prior hormone therapy - You have not been considered for Lu-PSMA treatment at your institution Talk to your doctor to see if this trial is right for you.